Sucampo Submits NDA For Constipation Agent Lubiprostone
This article was originally published in The Pink Sheet Daily
Executive Summary
Standard review is expected, setting a user fee deadline in January 2006. Sucampo plans to begin Phase III trials in constipation-predominant irritable bowel syndrome “soon.” The oral agent would be marketed by Takeda’s U.S. subsidiary.
You may also be interested in...
Takeda/Sucampo To Launch Constipation Agent Amitiza In Early Second Quarter
Co-promotion partner Takeda will focus sales activities on office-based gastroenterologists and primary care physicians, while Sucampo will target medical centers and the VA.
Takeda/Sucampo To Launch Constipation Agent Amitiza In Early Second Quarter
Co-promotion partner Takeda will focus sales activities on office-based gastroenterologists and primary care physicians, while Sucampo will target medical centers and the VA.
Novartis' Zelnorm Approved For Chronic Constipation Without Gender Restrictions
FDA approves the supplemental indication despite an advisory committee recommendation that tegaserod use be limited to women. The agency follows the committee's recommendation on use only in individuals under age 65.